(Q43409328)

23 November 2017

Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients (English)

1 reference

23 November 2017

1

Maurizio Zangari

1 reference

23 November 2017

17

Sagar Lonial

1 reference

23 November 2017

11

Robert Z Orlowski

1 reference

23 November 2017

15

Suzanne Trudel

1 reference

23 November 2017

13

Andrzej Jakubowiak

1 reference

23 November 2017

Monette Aujay

2

1 reference

23 November 2017

Fenghuang Zhan

3

1 reference

23 November 2017

Kristina L Hetherington

4

1 reference

23 November 2017

Tamara Berno

5

1 reference

23 November 2017

Ravi Vij

6

1 reference

23 November 2017

Sundar Jagannath

7

1 reference

23 November 2017

David Siegel

8

1 reference

23 November 2017

A Keith Stewart

9

1 reference

23 November 2017

Luhua Wang

10

1 reference

23 November 2017

Andrew Belch

12

1 reference

23 November 2017

George Somlo

14

1 reference

23 November 2017

Nizar Bahlis

16

1 reference

23 November 2017

Seema Singhal

18

1 reference

23 November 2017

Vishal Kukreti

19

1 reference

23 November 2017

Guido Tricot

20

1 reference

23 November 2017

1 June 2011

1 reference

European Journal of Haematology

23 November 2017

1 reference

23 November 2017

86

1 reference

23 November 2017

6

1 reference

23 November 2017

484-487

1 reference

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

23 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01602.X

Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01602.X

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01602.X

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01602.X

The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01602.X

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01602.X

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01602.X

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01602.X

Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01602.X

Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01602.X

A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01602.X

10.1111/J.1600-0609.2011.01602.X

21 January 2018

Identifiers

DOI

1 reference

23 November 2017

1 reference